Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23866601 | 1.00 | CYP2D6 (0.56) | CYP2D6CYP2C19KMT2AMEN1MMP1 | |
| SCHEMBL8633406 | 1.00 | CYP2D6 (0.56) | CYP2D6CYP2C19KMT2AMEN1MMP1 | |
| SCHEMBL8195763 | 0.84 | MEN1 (0.50) | CYP2D6CYP2C19KMT2AMEN1MMP1 | |
| SCHEMBL1582718 | 0.84 | MEN1 (0.50) | CYP2D6CYP2C19KMT2AMEN1MMP1 | |
| SCHEMBL3354440 | 0.81 | CYP2D6 (0.59) | CYP2D6CYP2C19KMT2AMEN1MMP1 | |
| SCHEMBL1583004 | 0.80 | MEN1 (0.47) | CYP2D6CYP2C19KMT2AMEN1MMP1 | |
| SCHEMBL15374903 | 0.78 | MEN1 (0.45) | CYP2D6CYP2C19KMT2AMEN1HPGD | |
| SCHEMBL18212154 | 0.78 | MEN1 (0.45) | CYP2D6CYP2C19KMT2AMEN1GAA | |
| SCHEMBL15374899 | 0.78 | MEN1 (0.45) | CYP2D6CYP2C19KMT2AMEN1HPGD | |
| SCHEMBL18212166 | 0.78 | MEN1 (0.45) | CYP2D6CYP2C19KMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194778-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LTD (GB) | 2017-01-18 | — | — | EP | claimed |
| US-20110190129-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2011-08-04 | — | — | US | claimed |
| EP-2194778-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Syngenta Limited (GB) | 2010-06-16 | — | — | EP | claimed |
| WO-2009027624-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-03-05 | — | — | WO | claimed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| US-20200316051-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-10-08 | — | — | US | disclosed |
| WO-2020025517-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | WO | disclosed |
| EP-2194778-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LTD (GB) | 2017-01-18 | — | — | EP | disclosed |
| EP-2001288-B1 | PROCESS FOR PRODUCING LACTAMIDE COMPOUNDS, NEW LACTAMIDE COMPOUNDS AND FORMULATIONS CONTAINING LACTAMIDE COMPOUNDS | SYNGENTA LTD (GB) | 2015-06-24 | — | — | EP | disclosed |
| CN-101784186-B | Improvements relating to organic compounds | SYNGENTA LTD. (GB) | 2014-10-08 | — | — | CN | disclosed |
| US-8420859-B2 | Formulations | SYNGENTA LIMITED (GB) | 2013-04-16 | — | — | US | disclosed |
| US-20110190129-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2194778-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Syngenta Limited (GB) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009027624-A3 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| US-20090227453-A1 | FORUMLATIONS | SYNGENTA LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| WO-2009027624-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027624-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-03-05 | — | — | WO | disclosed |
| EP-2001288-A2 | PROCESS FOR PRODUCING LACTAMIDE COMPOUNDS, NEW LACTAMIDE COMPOUNDS AND FORMULATIONS CONTAINING LACTAMIDE COMPOUNDS | Syngenta Limited (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007107745-A2 | PROCESS FOR PRODUCING LACTAMIDE COMPOUNDS, NEW LACTAMIDE COMPOUNDS AND FORMULATIONS CONTAINING LACTAMIDE COMPOUNDS | SYNGENTA LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316051-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CYP2D6 2908/4885CYP2C19 3103/4885KMT2A 1879/4885 |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | CYP2D6 1759/4885CYP2C19 1374/4885KMT2A 1579/4885 |
| US-20110190129-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | NR4A2, NR2C2, CYP4A22 | CYP2D6 113/4885CYP2C19 227/4885KMT2A 3695/4885 |
| US-20090227453-A1 | FORUMLATIONS | CBR3, NR1H3, NR2C2 | CYP2D6 48/4885CYP2C19 209/4885KMT2A 3300/4885 |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CYP2D6 2475/4885CYP2C19 2784/4885KMT2A 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.